object
spontan
intracerebr
hemorrhag
ich
caus
ruptur
small
blood
vessel
health
problem
ich
patient
hematoma
enlarg
critic
risk
factor
poor
outcom
tranexam
acid
antifibrinolyt
agent
use
reduc
hematoma
expans
analyz
risk
factor
hematoma
expans
ich
patient
compar
predict
hematoma
expans
ich
patient
use
tranexam
acid
method
perform
retrospect
analysi
ich
patient
underw
followup
comput
tomographi
scan
octob
octob
includ
patient
receiv
tranexam
acid
receiv
tranexam
acid
compar
also
analyz
risk
factor
patient
experi
hematoma
expans
respect
result
hematoma
expans
observ
patient
tranexam
acid
group
patient
receiv
tranexam
acid
statist
signific
differ
patient
receiv
tranexam
acid
multivari
logist
regress
analysi
risk
factor
hematoma
expans
spot
sign
maxim
diamet
mm
identifi
risk
factor
conclus
could
confirm
effect
tranexam
acid
hematoma
expans
ich
patient
spot
sign
maxim
diamet
hematoma
confirm
risk
factor
hematoma
expans
maxim
diamet
greater
mm
hematoma
close
monitor
spontan
intracerebr
hemorrhag
ich
caus
ruptur
small
blood
vessel
brain
major
health
problem
annual
incid
per
individu
account
total
stroke
compar
ischem
stroke
ich
critic
diseas
time
higher
mortal
morbid
accord
report
mortal
rate
ich
survivor
favor
function
outcom
month
patient
ich
hematoma
enlarg
critic
risk
factor
caus
poor
outcom
increas
mortal
therefor
prevent
hematoma
enlarg
goal
conserv
manag
howev
except
strict
control
blood
pressur
bp
know
prevent
hematoma
enlarg
ich
patient
accord
sever
articl
use
antifibrinolyt
agent
report
reduc
blood
loss
surgeri
prevent
hematoma
expans
howev
unlik
promis
find
relat
random
control
trial
shown
antifibrinolyt
agent
affect
rebleed
neurolog
deterior
mortal
cerebr
hemorrhag
consider
discrep
analyz
risk
factor
hematoma
expans
ich
patient
compar
predict
hematoma
expans
ich
patient
use
antifibrinolyt
agent
assess
patient
diagnos
spontan
ich
octob
octob
exclud
patient
symptom
develop
hour
also
exclud
patient
refus
treatment
old
age
chronic
diseas
person
issu
patient
underw
surgeri
first
comput
tomographi
ct
scan
eleven
patient
undergo
followup
ct
within
hour
exclud
therefor
treat
appropri
conserv
manag
includ
strict
bp
control
pain
control
includ
studi
studi
approv
institut
review
board
pusan
nation
univers
yangsan
hospit
irb
patient
neurolog
symptom
routin
evalu
neurosurgeon
admit
neurointens
care
unit
neurosurg
unit
seri
patient
includ
hemorrhag
due
intracrani
aneurysm
arterioven
malform
arterioven
fistula
cavern
malform
moyamoya
diseas
tumor
bleed
diseas
could
exclud
take
ct
angiographi
enhanc
ct
time
first
ct
tumor
bleed
suspect
patient
cancer
histori
confirm
magnet
reson
imag
mri
taken
week
cavern
malform
exclud
via
mri
hematoma
absorb
first
ct
taken
within
minut
arriv
emerg
room
second
ct
taken
within
hour
ct
taken
earli
chang
neurolog
symptom
glasgow
coma
scale
score
hematoma
size
measur
initi
second
ct
imag
maxim
diamet
longest
measur
intraparenchym
high
densiti
among
ct
axial
section
final
lesion
volum
calcul
multipli
area
obtain
section
slice
thick
ventricular
hemorrhag
exclud
hematoma
volum
calcul
calcul
difficulti
variou
definit
hematoma
expans
report
increas
hematoma
volum
baselin
imag
second
ct
scan
defin
hematoma
expans
increas
maximum
diamet
increas
volum
sinc
februari
use
antifibrinolyt
agent
combin
bp
pain
control
medic
patient
ich
ich
diagnos
via
ct
scan
patient
immedi
receiv
g
tranexam
acid
transamin
inject
intraven
bolu
g
period
minut
use
dose
base
sorimachi
report
wellknown
studi
tranexam
acidbas
ich
hemostasi
therefor
patient
receiv
tranexam
acid
octob
januari
compar
patient
administ
tranexam
acid
target
systol
bp
lower
mmhg
valu
determin
accord
sever
ich
guidelin
bp
monitor
continu
arteri
line
initi
high
bp
control
diltiazem
nicardipin
bolu
intraven
inject
maintain
systol
bp
mmhg
continu
intraven
administr
nicardipin
use
neurosurg
intens
care
unit
first
hour
admiss
better
bp
control
made
great
effort
reduc
pain
use
nonsteroid
antiinflammatori
drug
variou
analges
eg
narcot
patch
type
analges
visual
analog
scale
util
quantifi
pain
analges
use
patient
complain
pain
includ
headach
unconsci
patient
analges
use
bp
control
control
collect
wellknown
risk
factor
hematoma
expans
patient
data
use
electr
medic
record
pac
system
patient
age
sex
locat
hematoma
level
conscious
systol
bp
admiss
medic
histori
eg
hypertens
diabet
dyslipidemia
cardiovascular
diseas
chronic
kidney
diseas
ckd
alcohol
consumpt
smoke
statu
use
antiplatelet
agent
use
anticoagul
hematoma
volum
statist
analys
perform
use
spss
statist
version
ibm
corpor
armonk
ny
usa
continu
variabl
present
deviat
categor
variabl
present
number
percentag
student
ttest
analysi
fisher
exact
test
use
assess
betweengroup
differ
receiv
oper
characterist
roc
curv
creat
determin
optim
hematoma
volum
maxim
diamet
cut
point
sensit
specif
hematoma
expans
accord
second
ct
univari
multivari
logist
regress
analys
use
assess
risk
factor
hematoma
expans
multivari
logist
regress
perform
independ
variabl
select
factor
valu
p
univari
analys
result
present
odd
ratio
confid
interv
ci
statist
signific
set
p
tranexam
acid
appli
accord
protocol
patient
tabl
show
characterist
patient
receiv
tranexam
acid
statist
signific
differ
group
mean
age
sex
size
volum
hematoma
spot
sign
hematoma
bp
medic
histori
hypertens
diabet
mellitu
dyslipidemia
cardiovascular
diseas
stroke
alcohol
drug
use
antiplatelet
anticoagul
except
smoke
statu
ckd
although
signific
differ
characterist
patient
group
use
tranexam
acid
show
signific
reduc
incid
hematoma
expans
hematoma
expans
observ
patient
tranexam
acid
group
patient
control
group
analyz
risk
factor
involv
hematoma
expans
tabl
compar
group
experienc
hematoma
expans
signific
differ
maxim
diamet
hematoma
presenc
spot
sign
group
although
statist
signific
seem
associ
initi
hematoma
volum
smoke
need
pain
control
hematoma
expans
therefor
multivari
logist
regress
analysi
perform
determin
risk
factor
hematoma
expans
includ
variabl
tabl
show
result
maxim
diamet
hematoma
presenc
spot
sign
found
signific
risk
factor
hematoma
expans
hematoma
volum
maxim
diamet
cm
mm
hematoma
expans
group
mm
cm
nonhematoma
expans
group
respect
base
roc
curv
optim
cut
point
achiev
maxim
sensit
specif
maxim
diamet
hematoma
volum
mm
cm
respect
patient
hematoma
expans
patient
underw
conserv
manag
patient
receiv
hematoma
aspir
patient
receiv
craniotomi
ich
remov
tranexam
acid
synthet
deriv
amino
acid
lysin
serv
antifibrinolyt
revers
bind
lysin
receptor
site
plasminogen
molecul
bind
complet
block
interact
plasminogen
plasmin
lysin
residu
surfac
fibrin
therebi
prevent
proteolyt
action
plasmin
fibrin
inhibit
fibrinolysi
bleed
site
mechan
tranexam
acid
http
kjntorg
http
use
decad
multipl
surgic
disciplin
abil
reduc
intraop
blood
loss
need
blood
transfus
evid
suggest
tranexam
acid
may
also
reduc
postop
edema
ecchymosi
tranexam
acid
also
pass
bloodbrain
barrier
may
effect
hemorrhag
diseas
includ
intracrani
hemorrhag
light
concept
research
report
tranexam
acid
reduc
rebleed
aneurysm
subarachnoid
hemorrhag
sah
although
report
thromboembol
event
delay
cerebr
ischemia
also
increas
addit
recent
system
review
report
use
tranexam
acid
patient
nontraumat
sah
reduc
mortal
howev
find
statist
signific
anoth
intracrani
hemorrhag
studi
sorimachi
et
al
report
combin
rapid
administr
tranexam
acid
strict
bp
control
may
prevent
hematoma
growth
patient
ich
best
knowledg
evid
show
effect
tranexam
acid
ich
asid
studi
recent
sever
welldesign
clinic
trial
includ
evalu
plan
conduct
shown
statist
satisfactori
result
includ
reduc
hematoma
expans
clinic
outcom
therefor
studi
investig
effect
tranexam
acid
ich
way
similar
sorimachi
studi
result
show
statist
signific
ich
patient
rapid
administr
tranexam
acid
strict
conserv
manag
rate
patient
experienc
hematoma
expans
reduc
vs
use
tranexam
acid
cardiac
orthoped
spinal
deform
surgeri
shown
reduc
hemorrhag
intraop
transfus
howev
abovement
surgeri
hemorrhag
occur
mainli
muscl
connect
tissu
ich
occur
small
blood
vessel
therefor
direct
comparison
appropri
safeti
tranexam
acid
also
controversi
primari
issu
use
tranexam
acid
potenti
increas
risk
thromboembol
event
myocardi
infarct
ischem
stroke
deep
vein
thrombosi
pulmonari
embol
howev
recent
literatur
includ
metaanalysi
demonstr
tranexam
acid
associ
increas
incid
thromboembol
event
addit
complic
tranexam
acid
complic
nausea
vomit
abdomin
pain
difficult
evalu
patient
present
studi
show
limit
observ
durat
number
case
observ
complic
studi
show
maxim
diamet
hematoma
presenc
spot
sign
risk
factor
hematoma
expans
variabl
risk
factor
wellknown
hematoma
expans
studi
suggest
maxim
diamet
hematoma
greater
mm
close
monitor
possibl
hematoma
expans
previou
studi
identifi
hematoma
volum
predictor
hematoma
expans
howev
studi
fail
concur
possibl
research
directli
calcul
volum
accord
ct
slice
thick
contrast
maxim
diamet
hematoma
could
predict
hematoma
expans
easili
measur
accur
spot
sign
studi
extens
last
decad
might
strongest
individu
predictor
subsequ
hematoma
expans
one
believ
explan
spot
sign
might
repres
activ
bleed
rebleed
ruptur
vessel
reflect
contrast
extravas
ct
mri
scan
recent
modifi
spot
sign
black
hole
sign
nonenh
ct
scan
propos
radiolog
marker
similar
spot
sign
marker
also
strongli
associ
hematoma
expans
prognosi
paramet
includ
anticoagul
antiplatelet
medic
indic
statist
signific
result
suggest
small
number
case
adjust
paramet
includ
bp
pain
strictli
manag
accord
guidelin
studi
sever
limit
includ
retrospect
natur
data
collect
small
popul
result
welldesign
random
control
ongo
clinic
trial
prove
valu
find
retrospect
studi
statist
signific
patient
experienc
ich
rapid
administr
tranexam
acid
strict
conserv
manag
rate
patient
experienc
hematoma
expans
reduc
also
found
import
spot
sign
risk
factor
analysi
hematoma
size
greater
mm
close
monitor
possibl
hematoma
expans
